

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Biostime International Holdings Limited

合生元國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1112)

UNUSUAL PRICE AND TRADING VOLUME MOVEMENT

This announcement is made by Biostime International Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) at the request of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance, Chapter 571 of the laws of Hong Kong (the “SFO”).

The board of directors (the “Board”) of the Company has noted the increases in the price and the volume of the shares of the Company today. Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that save as disclosed below, the Board is not aware of any reasons for such movements or of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part XIVA of the SFO.

The Board has noted that the European Central Bank announced a quantitative easing policy which has caused the exchange rate of the Euro (€) against the RMB to decline sharply. As the Group’s import of infant formula from Europe to China, which are settled in Euro, represents a major part of the procurement cost of the Group, the decline of the value of the Euro against the RMB is expected to have a positive impact on the prospective gross margin of the Company.

Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the shares of the Company.

This announcement is made by the order of the Board. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

By Order of the Board
Biostime International Holdings Limited
Luo Fei
Chairman

Hong Kong, 26 January 2015

As at the date of this announcement, the executive directors of the Company are Mr. Luo Fei and Ms. Kong Qingjuan; the non-executive directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.